601 related articles for article (PubMed ID: 33763789)
1. Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Masuda N; Bando H; Yamanaka T; Kadoya T; Takahashi M; Nagai SE; Ohtani S; Aruga T; Suzuki E; Kikawa Y; Yasojima H; Kasai H; Ishiguro H; Kawabata H; Morita S; Haga H; Kataoka TR; Uozumi R; Ohno S; Toi M
Breast Cancer Res Treat; 2021 Jul; 188(1):117-131. PubMed ID: 33763789
[TBL] [Abstract][Full Text] [Related]
2. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
[TBL] [Abstract][Full Text] [Related]
3. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
4. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Kaklamani VG; Jeruss JS; Hughes E; Siziopikou K; Timms KM; Gutin A; Abkevich V; Sangale Z; Solimeno C; Brown KL; Jones J; Hartman AR; Meservey C; Jovanovic B; Helenowski I; Khan SA; Bethke K; Hansen N; Uthe R; Giordano S; Rosen S; Hoskins K; Von Roenn J; Jain S; Parini V; Gradishar W
Breast Cancer Res Treat; 2015 Jun; 151(3):629-38. PubMed ID: 26006067
[TBL] [Abstract][Full Text] [Related]
5. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
Fasching PA; Link T; Hauke J; Seither F; Jackisch C; Klare P; Schmatloch S; Hanusch C; Huober J; Stefek A; Seiler S; Schmitt WD; Uleer C; Doering G; Rhiem K; Schneeweiss A; Engels K; Denkert C; Schmutzler RK; Hahnen E; Untch M; Burchardi N; Blohmer JU; Loibl S;
Ann Oncol; 2021 Jan; 32(1):49-57. PubMed ID: 33098995
[TBL] [Abstract][Full Text] [Related]
7. Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
Zhang L; Wu Z; Li J; Zhu D; Yang L; Shao Y; Lin Y; Liu Z; Cao Y; Zhang G; Shang S; Zhang Y; Wang K
JCO Precis Oncol; 2023 Jan; 7():e2200337. PubMed ID: 36652665
[TBL] [Abstract][Full Text] [Related]
8. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
[TBL] [Abstract][Full Text] [Related]
9. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Llop-Guevara A; Loibl S; Villacampa G; Vladimirova V; Schneeweiss A; Karn T; Zahm DM; Herencia-Ropero A; Jank P; van Mackelenbergh M; Fasching PA; Marmé F; Stickeler E; Schem C; Dienstmann R; Florian S; Nekljudova V; Balmaña J; Hahnen E; Denkert C; Serra V
Ann Oncol; 2021 Dec; 32(12):1590-1596. PubMed ID: 34520831
[TBL] [Abstract][Full Text] [Related]
10. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
11. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer.
Lim B; Song J; Ibrahim NK; Koenig KB; Chavez-MacGregor M; Ensor JE; Gomez JS; Krishnamurthy S; Caudle AS; Shaitelman SF; Whitman GJ; Valero V
Oncologist; 2021 Feb; 26(2):e230-e240. PubMed ID: 33140515
[TBL] [Abstract][Full Text] [Related]
13. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Zhang L; Wu ZY; Li J; Lin Y; Liu Z; Cao Y; Zhang G; Gao HF; Yang M; Yang CQ; Zhu T; Cheng MY; Ji F; Li J; Wang K
Int J Cancer; 2022 Feb; 150(4):654-662. PubMed ID: 34591977
[TBL] [Abstract][Full Text] [Related]
15. Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).
Fontaine C; Renard V; Van den Bulk H; Vuylsteke P; Glorieux P; Dopchie C; Decoster L; Vanacker L; de Azambuja E; De Greve J; Awada A; Wildiers H
Breast Cancer Res Treat; 2019 Aug; 176(3):607-615. PubMed ID: 31069589
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.
de Pádua Souza C; Carneiro ASB; de Oliveira Lessa AC; Lacerda DC; Paiva CE; Zorzetto MMC; de Freitas AJA; Santana IVV; de Oliveira MA; Palmero EI; Marques MMC; Reinert T
Breast Cancer Res Treat; 2023 Nov; 202(1):57-65. PubMed ID: 37578666
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Sella T; Gal Yam EN; Levanon K; Rotenberg TS; Gadot M; Kuchuk I; Molho RB; Itai A; Modiano TM; Gold R; Kaufman B; Shimon SP
Breast; 2018 Aug; 40():141-146. PubMed ID: 29800932
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
Geyer CE; Sikov WM; Huober J; Rugo HS; Wolmark N; O'Shaughnessy J; Maag D; Untch M; Golshan M; Lorenzo JP; Metzger O; Dunbar M; Symmans WF; Rastogi P; Sohn JH; Young R; Wright GS; Harkness C; McIntyre K; Yardley D; Loibl S
Ann Oncol; 2022 Apr; 33(4):384-394. PubMed ID: 35093516
[TBL] [Abstract][Full Text] [Related]
19. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
[TBL] [Abstract][Full Text] [Related]
20. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Mayer EL; Abramson V; Jankowitz R; Falkson C; Marcom PK; Traina T; Carey L; Rimawi M; Specht J; Miller K; Stearns V; Tung N; Perou C; Richardson AL; Componeschi K; Trippa L; Tan-Wasielewski Z; Timms K; Krop I; Wolff AC; Winer EP
Ann Oncol; 2020 Nov; 31(11):1518-1525. PubMed ID: 32798689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
